Summary
The state of the art in acute myeloid leukaemia (AML) in 2016 is changing dramatically. This is the result of the availability of new techniques for genome sequencing leading to understanding of the AML ontogeny at the molecular level, redefining minimal residual disease status in daily practice, the optimised use of induction and post-remission strategies and the introduction of many novel agents. Hopefully this will ultimately lead to the long expected improvement in survival for our individual patients.
(BELG J HEMATOL 2016;7(4):137–42)
